FDA/SEC Communication Enhancement Effort Gauged At FDLI
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers should take extra care to present a uniform message to FDA and CMS concerning new devices to avoid running afoul of the Securities & Exchange Commission, Latham & Watkins Partner John Manthei advised April 15